74 Generic Drug Products Pass Consistency Evaluation; Qilu, Jichuan, Kelun Among Key Players
Easton Biopharmaceuticals
Developer, Manufacturer, and Distributor of Active Pharmaceutical Ingredients (APIs), High-End Chemical Drugs, and Biologics
SSY
Developer, Manufacturer, and Distributor of Intravenous Infusion Products
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
Kelun
Innovative Pharmaceutical R&D Company
Qilu PharmaceuticalYesSacubitril Valsartan Sodium Tablets, Oxaliplatin for Injection, Azithromycin for Injection, Sildenafil Citrate Orally Disintegrating Tablets, Sodium Hyaluronate Eye DropsFive varieties, including Kelun, have passed/been deemed to pass the consistency evaluation;Qingdao RuiNai MedicalSix peritoneal dialysis solutions have passed the evaluation.China Resources Sanjiu Medical & Pharmaceutical, SSY Group Limited, Jichuan Pharmaceutical, Hunan Warner PharmaceuticalMultiple pharmaceutical companies, including Kelun, Qilu Pharmaceutical, Chengdu Easton Bio Pharmaceuticals, and SSY Group Limited, have two products pass the evaluation on the same day.
See the table and mini-program below for details.
Table 1: Varieties Passed Evaluation on 10.30 (First to Pass Marked in Red)
Data Source:PharmCube Approved Drug Summary Database
END
Reply to the keyword "Report", access dozens of exclusive reports produced by Pharma Intelligence Cloud
Reply to the keyword "CSCO", Obtain 2023 CSCO Guidelines
Reply to the keyword " in the backgroundASCO", Obtain 2023 ASCO Abstract by Cancer Type
Reply to the keyword "First Generic in 2022", Obtain the list of first generic drugs approved in 2022
Reply to the keyword "Medical Insurance", Obtain the 2022 Medical Insurance Catalog
Contact us to experience more professional services from PharmaCloud. | ||||
WillDiscussion CombinedWork | GardenDistrict TakeWu | Database Consultation | Customization Service | Media Cooperation |
